A phase 2, double-blind, placebo-controlled, randomized, parallel-group, multicenter study to evaluate the efficacy and safety of 40mg/day KW-6002 (istradefylline) in subjects with restless legs syndrome

Trial Profile

A phase 2, double-blind, placebo-controlled, randomized, parallel-group, multicenter study to evaluate the efficacy and safety of 40mg/day KW-6002 (istradefylline) in subjects with restless legs syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 18 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top